Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 219 Neoplasms 15 Neoplasm Metastasis 12 Carcinoma, Intraductal, Noninfiltrating 10 Breast Neoplasms, Male 7 Breast Diseases 7 Breast Carcinoma In Situ 7 Advanced Breast Cancer 6 Triple Negative Breast Neoplasms 5 Ovarian Neoplasms 5 Endometrial Neoplasms 5 Neoplasms by Site 3 Breast Cancer Metastatic 3 Uterine Cervical Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasm Female 2 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Skin Diseases 1 Sexual Dysfunctions, Psychological 1 Sexual Dysfunction, Physiological 1 Seizures 1 Sarcoma 1 Recurrence 1 Quality of Life 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Osteoporosis 1 Multiple Endocrine Neoplasia Type 1 1 Low Grade Serous Ovarian Cancer 1

Interventions

Cyclophosphamide 151 Dexamethasone 140 Rituximab 83 fludarabine 78 Cytarabine 69 Lenalidomide 68 Bortezomib 63 fludarabine phosphate 62 Gemcitabine 62 venetoclax 54 Etoposide 53 pembrolizumab 52 pomalidomide 48 Paclitaxel 48 Cisplatin 47 Carboplatin 47 Peripheral Blood Stem Cell Transplantation 46 Filgrastim 40 Radiotherapy 39 Calcium Dobesilate 36 Busulfan 36 Methotrexate 34 Melphalan 34 Bevacizumab 33 carfilzomib 32 Cyclosporine 32 Azacitidine 32 Mycophenolic Acid 29 Vincristine 28 Temozolomide 28

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Recurrence × Anastrozole × Clear all

NCT00256698 2012-08-01

FACT

AstraZeneca

Phase 3 Completed

514 enrolled 13 charts

Breast Neoplasms, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡